← Leaderboards
Dan Paul Zandberg
University Of Pittsburgh At Pittsburgh
$1,056,227
Attributed
$2,797,209
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,797,209 · 3
By mechanism
R01$2,762,709 · 2
P30$34,500 · 1
Top collaborators
- Brenda B. Diergaarde4 shared
- Theresa L. Whiteside4 shared
- Riyue Bao1 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Jennifer R Grandis$109,711,044
- Hassane M Zarour$16,372,397
- Robert L Ferris$24,076,317
- Theresa L. Whiteside$29,550,469
- John F McDyer$10,518,722
Others in their field
Other Emerging Leaders on “Immune”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$181,310,675
- Kevin Urdahl · Seattle Children'S Hospital$84,741,409
- Ted Ross · University Of Georgia$74,507,826
- Yunda Huang · Fred Hutchinson Cancer Center$73,602,469
- Tony Moody · Duke University$66,767,417
Research focus
ImmuneMolecularTreatment ResponseHead And Neck CancerProgramsResolutionTherapy ResistantAftercareImproved OutcomeMediatingPhenotypePredictive MarkerResistanceCombined Modality TherapyCancer TherapyImmune Checkpoint InhibitorHead And Neck Squamous Cell CarcinomaHpv-Negative Head And Neck CancerImmunotherapyCellsLinkMalignant NeoplasmsBiological MarkersNeoplastic Cell
Grant awards (6)
Small extracellular vesicles as biomarkers of prognosis and response to therapy in head and neck cancer$700,037
R01 · FY2025 · DE
Immune Exclusion in Cancer Immunotherapy$604,941
R01 · FY2025 · DE
Small extracellular vesicles as biomarkers of prognosis and response to therapy in head and neck cancer$686,036
R01 · FY2024 · DE
Small extracellular vesicles as biomarkers of prognosis and response to therapy in head and neck cancer$130,976
R01 · FY2024 · DE
Small extracellular vesicles as biomarkers of prognosis and response to therapy in head and neck cancer$640,719
R01 · FY2023 · DE
Head and Neck Cancer Program (Project-010)$34,500
P30 · FY2019 · CA · contact PI